...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Experimental Hematology Oncology >Frontline therapies for untreated chronic lymphoid leukemia
【24h】

Frontline therapies for untreated chronic lymphoid leukemia

机译：Frontline疗法未经治疗的慢性淋巴白血病

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Therapy for chronic myeloid leukemia (CLL) is going through a major paradigm shift. Combination chemoimmunotherapy regimens have been the frontline therapies for CLL, whereas chlorambucil remained the standard frontline therapy for older patients (65?years or older) with CLL until recently. Monoclonal antibodies including rituximab, ofatumumab and obinutuzumab have been used for CLL therapy. Novel immunotherapeutics with chimeric antigen receptor (CAR) engineered T cells is rapidly migrating to clinical applications. Targeted therapies with small molecule inhibitors against Bruton tyrosine kinase (BTK) such as ibrutinib and acalabrutinib are playing a major role for treatment of patients with either treatment-na?ve or refractory/relapsed CLL. Several major clinical trials including RESONATE-2, iLLUMINATE, ALLIANCE, ECOG 1912, CLL10, CLL14 as well as ibrutinib plus venetoclax have been ongoing in patients with untreated CLL. Frontline therapy of patients with untreated CLL appears to be shifting from chemotherapy to chemotherapy-free regimens. This review summarized latest development for frontline therapies of untreated CLL.
机译：慢性髓性白血病（CLL）的治疗正在进行一个主要的范式转变。组合化疗疗法方案一直是CLL的前线疗法，而氯姆米尔仍然是老年患者（65岁或以上）的标准前线治疗，直到最近直到CLL。包括Rituximab，ofatumumab和Obinutuzumab的单克隆抗体已被用于CLL疗法。具有嵌合抗原受体（CAR）工程T细胞的新型免疫治疗迅速迁移到临床应用。具有针对诸如Ibrutinib和Acalabrutinib的小分子抑制剂的靶向疗法，例如Ibrutinib和Acalabrutinib，用于治疗治疗患者或难治性/复发CLL的主要作用。几种主要临床试验，包括共振-2，照明，联盟，ECOG 1912，CLL10，CLL14以及Ibrutinib Plus venetoclax在未处理的CLL患者中一直在进行。未经治疗的CLL患者的前线治疗似乎从化疗转移到无化学疗法的方案。本综述总结了未经治疗的CLL前线疗法的最新开发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号